Itraconazole Sugar Free Syri Pharma (Itraconazole)

Itraconazole is an azole antifungal used to treat a range of systemic and superficial fungal infections.

• Aspergillosis: reduces fungal growth in the lungs, improves respiratory symptoms and prevents disease progression.
• Candidiasis (oropharyngeal and esophageal): eradicates Candida species from mucosal surfaces, relieving pain and dysphagia.
• Dermatophytosis: eliminates dermatophyte infection of skin, hair and nails, leading to clearance of lesions.
• Blastomycosis: clears Blastomyces organisms from pulmonary and disseminated sites, aiding recovery.
• Histoplasmosis: treats Histoplasma capsulatum infection, preventing systemic spread and organ damage.

• Itraconazole inhibits the fungal enzyme lanosterol 14α‑demethylase, a cytochrome P450 isoform required for conversion of lanosterol to ergosterol. By blocking ergosterol synthesis, the drug disrupts the integrity of the fungal cell membrane, leading to increased permeability and inhibition of fungal growth. The inhibition is competitive and results in accumulation of toxic sterol intermediates, further compromising membrane function and inhibiting fungal replication.

Itraconazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild stomach upset.
• Headache: transient cranial discomfort.
• Diarrhea: loose stools.
• Elevated liver enzymes: mild transaminase increase.
• Abdominal pain: discomfort in the stomach area.
• Rash: mild skin redness or itching.
• Fatigue: feeling of tiredness or weakness.

Serious or Rare Side Effects

• Hepatotoxicity: severe liver injury or failure.
• Cardiac arrhythmias: QT prolongation and irregular heartbeat.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hepatic failure: acute liver dysfunction requiring hospitalization.
• Visual disturbances: blurred vision or photophobia.

When prescribing itraconazole, several precautions should be observed to minimize risk.

• Liver function monitoring: assess baseline transaminases and repeat periodically during therapy to detect hepatotoxicity.
• Drug interactions: review all concomitant medications that affect CYP3A4 metabolism to avoid reduced efficacy or toxicity.
• Cardiac assessment: avoid use in patients with known QT prolongation, arrhythmias, or severe heart failure.
• Pregnancy and lactation: prescribe only when benefits outweigh potential risks, as safety data are limited.
• Renal impairment: consider dose adjustment or close monitoring in patients with severe kidney dysfunction.
• Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Itraconazole has a notable potential for drug‑drug interactions due to its effect on cytochrome P450 enzymes.

Major Interactions (Avoid)

• Simvastatin: risk of severe myopathy and rhabdomyolysis.
• Cisapride: can cause life‑threatening arrhythmias.
• Rifampicin: markedly reduces itraconazole plasma levels, compromising efficacy.
• Ketoconazole: additive hepatotoxicity risk.
• St. John’s wort: induces metabolism leading to therapeutic failure.

Moderate Interactions (Monitor Closely)

• Calcium channel blockers (e.g., verapamil): may increase itraconazole levels, requiring dose adjustment.
• Anticoagulants (warfarin): monitor INR for enhanced anticoagulant effect.
• Oral contraceptives: efficacy may be reduced; advise alternative contraception.
• Macrolide antibiotics (e.g., erythromycin): may increase serum concentrations, watch for toxicity.